No evidence for PALB2 methylation in high-grade serous ovarian cancer

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Mikeska, Thomas ^a,b   Alsop, Kathryn ^a,b   Mitchell, Gillian ^a   Bowtell, David Dl ^a,b   Dobrovic, Alexander ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

DNA methylation; Fanconi anaemia; MS HRM; Ovarian cancer; PALB2

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; PROTEIN; PROTEIN PALB2; UNCLASSIFIED DRUG;

ARTICLE; DNA METHYLATION; GENE MUTATION; GENE SILENCING; HIGH GRADE SEROUS OVARIAN CANCER; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL;

EID: 84876897950     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-26     Document Type: Article

References (21)

1. The genesis and evolution of high-grade serous ovarian cancer. Bowtell DD, Nat Rev Cancer 2010 10 803 808 10.1038/nrc2946 20944665
2. Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research Network, Nature 2011 474 609 615 10.1038/nature10166 21720365
3. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the australian ovarian cancer study group. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G, J Clin Oncol 2012 30 2654 2663 10.1200/JCO.2011.39.8545 22711857
4. Hallmarks of 'BRCAness' in sporadic cancers. Turner N, Tutt A, Ashworth A, Nat Rev Cancer 2004 4 814 819 10.1038/nrc1457 15510162 (Pubitemid 39331153)
5. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Banerjee S, Kaye S, Curr Oncol Rep 2011 13 442 449 10.1007/s11912-011-0193-9 21913063
6. PALB2/FANCN: recombining cancer and fanconi anemia. Tischkowitz M, Xia B, Cancer Res 2010 70 7353 7359 10.1158/0008-5472.CAN-10-1012 20858716
7. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J, BMC Med Genet 2010 11 20 20122277
8. Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region. Prokofyeva D, Bogdanova N, Bermisheva M, Zinnatullina G, Hillemanns P, Khusnutdinova E, Dörk T, Clin Genet 2012 82 100 101 10.1111/j.1399-0004.2011.01824.x 22310028
9. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P, Cancer Res 2008 68 998 1002 10.1158/0008-5472.CAN-07-2418 18281473 (Pubitemid 351272217)
10. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Wojdacz TK, Dobrovic A, Nucleic Acids Res 2007 35 41 10.1093/nar/gkm013 17289753 (Pubitemid 47061680)
11. Methylation-sensitive high resolution melting for the rapid analysis of DNA methylation. Mikeska T, Dobrovic A, Epigenetics: a reference manual Norwich, UK: Caister Academic Press, Craig JM, Wong NC, 2011 325 335
12. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer Study (Ovarian Cancer) Australian Ovarian Cancer Study Group, Int J Cancer 2008 122 170 176 10.1002/ijc.23017 17721999 (Pubitemid 350209992)
13. Analysing DNA methylation using bisulphite pyrosequencing. Mikeska T, Felsberg J, Hewitt CA, Dobrovic A, Methods Mol Biol 2011 791 33 53 10.1007/978-1-61779-316-5-4 21913070
14. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Huang KT, Dobrovic A, Yan M, Karim RZ, Lee CS, Lakhani SR, Fox SB, Breast Cancer Res Treat 2010 124 555 565 10.1007/s10549-010-0970-4 20563638
15. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM, Gynecol Oncol 2012 124 582 588 10.1016/j.ygyno.2011. 11.026 22115852
16. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Mikeska T, Candiloro IL, Dobrovic A, Epigenomics 2010 2 561 573 10.2217/epi.10.32 22121974
17. Closed-tube PCR methods for locus-specific DNA methylation analysis. Candiloro IL, Mikeska T, Dobrovic A, Methods Mol Biol 2011 791 55 71 10.1007/978-1-61779-316-5-5 21913071
18. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ, Clin Cancer Res 2005 11 6422 6430 10.1158/1078-0432.CCR-05-0508 16166416 (Pubitemid 41338978)
19. Origins and molecular pathology of ovarian cancer. Bell DA, Mod Pathol 2005 18 Suppl 2 19 S32 15761464
20. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, Shih IM, Am J Surg Pathol 2010 34 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
21. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD, Australian Ovarian Cancer Study Group, Clin Cancer Res 2011 17 2538 2548 10.1158/1078-0432.CCR-10- 3314 21343371